Jun 9, 2026 08:30PM
Jun 9, 2026 08:30PM
Mar 18, 2026 10:03AM
Mar 18, 2026 06:33AM
Mar 17, 2026 04:08PM
Mar 17, 2026 02:45PM
Mar 17, 2026 08:30AM Aldeyra receives FDA rejection for dry eye drug reproxalap
Mar 17, 2026 08:30AM
Dec 16, 2025 03:57AM
Dec 15, 2025 07:30PM
Nov 13, 2025 07:00AM
Nov 13, 2025 07:00AM
Oct 28, 2025 07:01AM
Oct 28, 2025 07:01AM Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Oct 8, 2025 12:58PM
Aug 28, 2025 07:02AM
Aug 28, 2025 07:01AM
Aug 19, 2025 07:01AM
Aug 19, 2025 07:01AM
Aug 8, 2025 12:20PM
Jul 24, 2025 07:01AM Aldeyra gets European orphan designation for retinitis pigmentosa drug
Jul 24, 2025 07:00AM
Jul 17, 2025 07:02AM
Jul 17, 2025 07:00AM
Jun 26, 2025 08:18AM
Jun 26, 2025 07:00AM
Jun 26, 2025 07:00AM
Jun 18, 2025 03:02PM BTIG on Aldeyra Therapeutics (ALDX): 'Reproxalap Has Some Unique Attributes'
Jun 17, 2025 07:02AM
Jun 17, 2025 07:00AM
May 18, 2025 10:00AM
May 13, 2025 01:22PM
May 9, 2025 08:00AM
May 6, 2025 07:08AM
May 5, 2025 06:34PM Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
May 5, 2025 02:12PM
May 4, 2025 08:18AM
May 2, 2025 03:33PM
May 1, 2025 03:18PM
Apr 30, 2025 07:36AM
Apr 29, 2025 11:16AM
Apr 28, 2025 07:11AM ALDX SHAREHOLDER REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about Securities Investigation
Apr 26, 2025 07:08AM
Apr 25, 2025 12:57PM
Apr 24, 2025 07:36AM
Apr 22, 2025 07:17AM
Apr 21, 2025 02:30PM
Apr 20, 2025 07:37AM
Apr 18, 2025 03:23PM ALDX INVESTOR NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law About How to Potentially Recover Losses
Apr 17, 2025 03:11PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All